Acticor Biotech (XPAR:ALACT) Debt-to-Asset : 0.49 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Debt-to-Asset?

Acticor Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €2.71 Mil. Acticor Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €4.34 Mil. Acticor Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was €14.30 Mil. Acticor Biotech's debt to asset for the quarter that ended in Jun. 2023 was 0.49.

Acticor Biotech Debt-to-Asset Historical Data

The historical data trend for Acticor Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Debt-to-Asset Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.11

0.07

0.23

0.15

0.61

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial				0.35	0.15	0.23	0.61	0.49

Competitive Comparison of Acticor Biotech's Debt-to-Asset

For the Biotechnology subindustry, Acticor Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acticor Biotech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's Debt-to-Asset falls into.

Acticor Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Acticor Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.801	+	7.062)	/	12.943
	=	0.61

Acticor Biotech's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.705	+	4.342)	/	14.302
	=	0.49

Acticor Biotech (XPAR:ALACT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Acticor Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (XPAR:ALACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

7V7:Germany

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines